- Home
- OPT vs PZC Comparison
OPT vs PZC Comparison
Compare OPT & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- PZC
- Stock Information
- Founded
- OPT 1984
- PZC 2002
- Country
- OPT Australia
- PZC United States
- Employees
- OPT N/A
- PZC N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- PZC Investment Managers
- Sector
- OPT Health Care
- PZC Finance
- Exchange
- OPT Nasdaq
- PZC Nasdaq
- Market Cap
- OPT 201.5M
- PZC 163.2M
- IPO Year
- OPT 2020
- PZC N/A
- Fundamental
- Price
- OPT $3.24
- PZC $7.50
- Analyst Decision
- OPT Strong Buy
- PZC
- Analyst Count
- OPT 2
- PZC 0
- Target Price
- OPT $14.00
- PZC N/A
- AVG Volume (30 Days)
- OPT 10.8K
- PZC 48.2K
- Earning Date
- OPT 08-30-2024
- PZC 01-01-0001
- Dividend Yield
- OPT N/A
- PZC 4.68%
- EPS Growth
- OPT N/A
- PZC N/A
- EPS
- OPT N/A
- PZC N/A
- Revenue
- OPT $261,859.00
- PZC N/A
- Revenue This Year
- OPT N/A
- PZC N/A
- Revenue Next Year
- OPT $55,563.16
- PZC N/A
- P/E Ratio
- OPT N/A
- PZC N/A
- Revenue Growth
- OPT N/A
- PZC N/A
- 52 Week Low
- OPT $1.60
- PZC $6.30
- 52 Week High
- OPT $4.40
- PZC $8.20
- Technical
- Relative Strength Index (RSI)
- OPT 70.30
- PZC 73.24
- Support Level
- OPT $2.84
- PZC $7.26
- Resistance Level
- OPT $3.19
- PZC $7.29
- Average True Range (ATR)
- OPT 0.14
- PZC 0.06
- MACD
- OPT 0.01
- PZC 0.02
- Stochastic Oscillator
- OPT 100.00
- PZC 100.00
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.